目的: 分析新型冠状病毒性肺炎 （COVID-19） 患者在接受抗病毒药物联用治疗中发生的药物不良反应及其药学监护。方法: 收集医院收治的 COVID-19 患者在接受抗病毒药物联用治疗中的药物不良反应患者 102 例病历资料,分析其不良反应累及系统或器官和临床表现、不良反应发生情况,探究其实施药学监护方法,以及不良反应的发生与患者性别、年龄和合并基础疾病的相关性。结果: 102 例 COVID-19 患者中,抗病毒药物所致不良反应 70 例,其发生率为 68.63%;药物不良反应所累及系统或器官主要在消化系统、血液系统、神经系统、肝脏、皮肤及心脏;药物不良反应的发生与患者性别、年龄无相关性（P>0.05）,但其与患者伴有基础疾病具有相关性(P<0.05)。结论: 临床多种抗病毒药物联用于治疗 COVID-19 患者,应重视此类药品的不良反应,加强药学监护,以确保用药的有效性和安全性。
Abstract
Objective: To analyze the adverse drug reactions (ADRs) of antiviral drugs during medication of patients with COVID-19 and its pharmaceutical care. Methods: The medical records of 102 COVID-19 patients, who had ADRs after receiving antiviral drugs combination therapy, were collected. The involved organs/system, clinical manifestations and other situations of ADRs were analyzed in order to explore the implementation of pharmaceutical care and the relationship between ADRs and gender, age and underlying diseases Results: Of 102 COVID-19 patients, 70 cases (68.63%) had ADRs caused by antiviral drugs. The organs/systems involved in ADR mainly included digestive system, blood system, nervous system, liver, skin and heart. The occurrence of ADRs had no correlation with patients' gender and age(P>0.05), but has correlation with patients' underlying diseases(P< 0.05). Conclusion: When the COVID-19 patients were treated with combination of multiple antiviral drugs, monitoring adverse reactions and strengthening pharmaceutical care should be carried out in order to ensure the safety and effectiveness of medication.
关键词
新型冠状病毒性肺炎 /
抗病毒药物 /
药物不良反应 /
药学监护
{{custom_keyword}} /
Key words
COVID-19 /
antiviral drug /
ADRs /
pharmaceutical care
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Callaway E, Cyranoski D, Mallapaty S, et al. The coronavirus pandemic in five powerful charts[J]. Nature, 2020,579(7800):482-483.
[2] 国家卫生健康委员会.新型冠状病毒肺炎疫情最新情况[EB/OL]. http://www.nhc.gov.cn/xcs/yqfkdt/202005/7a15de623e794e8180397e8f6e74af4b.shtml.
[3] 国家卫生健康委员会.关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[EB/OL].http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm.
[4] 中国临床试验注册中心.中国临床试验[Z].http://www.chictr.org.cn/index.aspx.
[5] 中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组. 新型冠状病毒肺炎流行病学特征分析[J] . 中华流行病学杂志,2020,41(2): 145-151.
[6] World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 13 March 2020 [EB/OL]. https://apps.who.int/iris/handle/10665/331446.
[7] Michael S. Saag MD. The Sanford Guide Web Edition: Kaletra[M].2018-08-29.
[8] 陈泳伍,唐丽琴,张圣雨,等.α 干扰素雾化治疗在新型冠状病毒肺炎中的合理使用及药学监护[J].中国医院药学杂志,40(6):632-635.
[9] Ng J, Chiu YL, Awni W, et al. Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants[J]. J Clin Pharmacol, 2012, 52(8):1248-1254.
[10] Lopinavir and ritonavir tablets. prescribing information[J].North Chicago, IL:AbbVie Inc, 2018, 3.
[11] 曹瑜 .盐酸阿比多尔片在治疗急性呼吸道病毒感染中的安全性与有效性观察[J].中国现代药物应用,2018,12(17):101-103
[12] 申昆玲,尚云晓,张国成,等.α干扰素在儿科临床合理应用专家共识[J].中华实用儿科临床杂志,2018,33(17):1301-1308.
[13] Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19[J]. New Engl J Med, 2020, 382(19): 1787-1799.
[14] Xu XW, Wu XX, Jiang XG, et al. Clincal findings in group of patients infected with the 2019 novel coronavirus (SARS-Cov2) outside of Wuhan, China: retrospective case series[J]. BJM, 2020, 368: m606.
[15] Lan N, Nguyet T, BT Aurélie, et al. Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam[J]. Plos One, 2014, 9(1): e84866.
[16] Li L, Chen N, Kong LM, et al. Antiviral therapeutics for 2019 novel coronavirus infection in special populations[J].Chin J Mod Appl Pharm, 2020, 37(3):257-263.
[17] 陈军,凌云,席秀红,等.洛匹那韦利托那韦和阿比多尔用于治疗新型冠状病毒肺炎的有效性研究[J].中华传染病杂志,2020(02):86-89.
[18] 姜赛平,李璐,茹仁萍,等. 2019冠状病毒病(COVID-19)重型、危重型患者用药管理经验[J].浙江大学学报(医学版),49(2):158-169.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
*1乐清市科技局防疫临床应用科研攻关项目 (X202009)
{{custom_fund}}
PDF(1842 KB)
